A drug discovery company dedicated to developing treatments for Neurofibromatosis Type 1

INFIXION’S MISSION

To eradicate the negative consequences of NF1 via drug treatment

The mission of iNFixion Bioscience, a San Diego based drug discovery company, is to develop drug therapies to treat and prevent the progression of all symptoms associated with NF1, a rare genetic disorder impacting approximately 1 in 3000 people worldwide.

NF1 is caused by one of many possible genetic mutations in the NF1 gene. Mutations in this gene can be inherited (50% of cases), or can result from a spontaneous new mutation at conception. The NF1 gene is responsible for making a large and multifunctional protein called Neurofibromin which is produced in many cells throughout the body. Neurofibromin is known to regulate many important functions, including the control of cell division (i.e. tumors), as well as the proper functioning of brain, skeletal, muscular- and cardiovascular systems. As a consequence of NF1 mutations, tumors can grow along nerves anywhere in the body and other serious symptoms such as skin lesions, neurocognitive/social deficits, chronic pain, and bone abnormalities are common. Furthermore, people with NF1 mutations have an increased risk of both cancer and cardiovascular disease.

iNFixion’s unique approach to NF1 is to correct a key underlying genetic ‘mechanism of action’, namely the lack of functional Neurofibromin protein, by enhancing the affected person’s natural ability to both produce and maintain healthy Neurofibromin protein. By correcting this root cause mechanism, we believe that a fundamental and preventive impact on disease symptoms, and disease progression, will be achieved.

Latest news

iNFixion Bioscience announces second NIH SBIR Phase 1 Grant award

iNFixion Bioscience announced today that it had been granted its second NIH Phase 1 SBIR Grant award from the National Institute of Neurological Disorders and Stroke (NINDS).  This 18-month grant, titled "Inhibition of NF1 Protein Degradation…

iNFixion Bioscience completes NIH I-Corps™ commercialization program

The core team at iNFixion Bioscience has successfully completed the prestigious NIH I-Corps™ commercialization program.  In addition to a commercialization curriculum, the program included teh requirement of conducting interviews with over…

iNFixion awarded NIH SBIR grant; Enters JLABS Accelerator; Hires PhD Researcher

Infixion Bioscience announces it has designed and validated a new monoclonal antibody against NF1 protein. This new NF1-specific reagent is proving to be mInfixion Bioscience announces it has designed and validated a new monoclonal antibody against NF1 protein. This new NF1-specific reagent is proving to be m

iNFixion Bioscience announces effort to develop new NF1 monoclonal antibody

iNFixion Bioscience announced today its commitment to developing a new monoclonal antibody against NF1 protein. This NF1-specific reagent will be developed in rabbits using full-length NF1 protein as the immunogen, with the program goal being…